• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PainReform Ltd.

    10/1/25 9:29:56 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    PAINREFORM LTD. - 1801834 - 2025
    0001801834false--12-31Q2

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

     Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
     
    Pursuant to Rule 13a-16 or 15d-16
     of the Securities Exchange Act of 1934
     
    For the month of October 2025
     
    Commission File Number: 001-39481
     
    PainReform Ltd.
     (Translation of registrant’s name into English)
     
    65 Yigal Alon St., Tel Aviv 6744316
     Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
     
    Form 20-F ☒      Form 40-F ☐
     
    This Form 6-K, excluding the press release attached hereto as Exhibit 99.3, is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485, 333-277594, 333-283655 and 333-286941), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. .

     

    On October 1, 2025, PainReform Ltd. (the “Company”) issued a press release announcing its financial results for the six months ended June 30, 2025. The Company is also publishing its unaudited condensed financial statements, as well as its operating and financial review as of June 30, 2025 and for the six months then ended. Attached hereto are the following exhibits.
     
    99.1
    Unaudited Condensed Financial Statements as of June 30, 2025
     
     
    99.2
    Operating and Financial Review as of June 30, 2025 and for the six months then ended
     
     
    99.3
    Press Release dated October 1, 2025
     
    In addition, effective September 30, 2025, Professor Eli Hazum resigned from the Company’s Board of Directors due to personal reasons. Professor Hazum’s resignation was not the result of any disagreement with the Company or its management. In his place, Asaf Shavit was appointed to serve as a member of the Board of Directors, effective immediately.
     
    Mr. Shavit has more than 35 years of experience providing audit, tax and financial advisory services to public and private companies, including public corporations and subsidiaries of foreign entities. His areas of expertise include audits of financial statements, budget planning and control, taxation, mergers and acquisitions, corporate liquidations, valuations, and complex cross-border and capital markets transactions. He currently serves as Managing Partner at Moalem-Shavit & Co., Certified Public Accountants, since 1995, where he leads a team of more than 14 professionals. Mr. Shavit holds a B.A. in Accounting, Economics and Business Management and an M.B.A. in Business Management with a concentration in Finance and Banking. He is also a Certified Public Accountant.
     

    Exhibit Index
     
    Exhibit
    No.
     
    Description
     
     
     
    99.1
     
    Unaudited Condensed Financial Statements as of June 30, 2025
    99.2
     
    Operating and Financial Review as of June 30, 2025 and for the six months then ended
    99.3
     
    Press Release dated October 1, 2025
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    Date: October 1, 2025
    PAINREFORM LTD.
     
     
     
     
     
     
    By:
    /s/ Ehud Geller
     
     
     
    Ehud Geller
     
     
     
    Executive Chairman of the Board and Interim Chief Executive Officer
     
     

    Get the next $PRFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    10/1/25 9:29:56 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/19/25 8:45:37 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/13/25 4:16:22 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PainReform Provides Business Update for the Six Months Ended June 30, 2025

    TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D following partially positive efficacy signals in postoperative painExpanded DeepSolar with completion of Smart Energy Management app, acceptance into NVIDIA Connect Program, and successful completion

    10/1/25 9:27:49 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform/DeepSolar Accepted into NVIDIA Connect Program

    TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced that DeepSolar, PainReform's solar energy business unit developing next-generation AI-driven solar analytics, has been accepted into the prestigious NVIDIA Connect Program. This program is NVIDIA's premier development track for independent software vendors building transformative AI-based solutions across sectors. Participation in the program provides DeepSolar with access to NVIDIA's industry-leading AI frameworks, development tools, and engineering support. This future collaboration will support efforts to advance DeepSolar Predict, the company's breakthrough solar forecasting solution

    8/19/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

    TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio, Inc., a privately held Boston-based biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. With this transaction, PainReform has acquired a majority equity interest in LayerBio and plans to initiate the next clinical trial of OcuRing™-K, LayerBio's lead investigational product for pain and inflammation control following cataract surgery. This transaction positions PainReform to potentially address a large and growing clinical need in the global catarac

    8/13/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care